Prelude Therapeutics Price Pattern Analysis
| PRLD Stock | USD 5.15 0.31 6.40% |
Momentum
OversoldOverbought
56 · Buy Extended
Headline activity for Prelude Therapeutics is directly compared against price movement for pattern recognition. Values reflect relative positioning against peer attention patterns.
Prelude Therapeutics Current Signal Summary
Prelude Therapeutics's momentum reading (RSI at 61) sits in bullish territory, while the expected daily return of 1.6% is positive. Daily volatility at 8.28% is elevated, widening the range of near-term outcomes. Overall, signals for Prelude Therapeutics are mixed — momentum and returns are positive but sentiment leans negative, which could indicate skepticism.
Prelude Therapeutics's hype profile summarizes how attention and headline activity relate to recent performance. Volatility and performance cues alongside headline activity help assess the reliability of sentiment signals.
Prelude Therapeutics Post-Event Predicted Price | $ 5.15 |
Hype indicators alongside forecasting models, technical studies, and analyst consensus provide breadth. Momentum and earnings context provide additional reference points for interpretation.
Statistical evidence for mean reversion in Prelude Therapeutics' appears through its tendency to revert after extreme valuations. Under mean reversion theory, Prelude Therapeutics' price extremes are viewed as temporary dislocations that may self-correct. Mean reversion in Prelude Therapeutics' is often observed around historical valuation multiples. Historical data for Prelude Therapeutics shows that extreme valuations have tended to normalize over multi-year periods.
Post-Sentiment Price Density Analysis
The probability distribution for Prelude Therapeutics' predicted price encodes the full spectrum of outcomes by estimated likelihood. Confidence intervals from Prelude Therapeutics' distribution widen as the forecast horizon extends, reflecting compounding uncertainty. Comparing the width of Prelude Therapeutics' upside distribution against the downside reveals the risk-reward asymmetry for Prelude Therapeutics. Prelude Therapeutics' predicted outcome range provides a realistic frame for what the model considers plausible for Prelude Therapeutics.
Next price density |
| Expected price to next headline |
Estimated Post-Sentiment Price Volatility
After analyzing Prelude Therapeutics' historical price reactions to major news, we derive upside and downside boundaries for Prelude Therapeutics. Prelude Therapeutics' post-sentiment downside and upside margins for the prediction period are 0.26 and 13.43, respectively. This analysis complements technical and fundamental research by adding a news dimension to Prelude Therapeutics' forecasting.
Current Value
The after-hype framework applied to Prelude Therapeutics assumes a 3 months review window and focuses on post-sentiment normalization rather than raw momentum. The objective is to separate event-driven enthusiasm from a more stable price path once the market absorbs the catalyst.
Price Outlook Analysis
Big price swings in a Company such as Prelude Therapeutics are not always tied to earnings or company news. When news about Prelude Therapeutics picks up, it can start a cycle where attention feeds more price action. Identifying the drivers behind Prelude Therapeutics' momentum clarifies whether the move is fundamentally supported.
| Expected Return | Period Volatility | Sentiment Sensitivity | Peer Sensitivity | News Density | Peer Density | Next Expected Sentiment |
1.60 | 8.28 | 0.00 | 0.18 | 0 Events | 2 Events | Within a week |
| Latest Traded Price | Expected Post-Event Price | Potential Return on Next Event | Post-Sentiment Volatility | |
5.15 | 5.15 | 0.00 |
|
Market Sentiment Timeline
Prelude Therapeutics is at this time traded for 5.15. Prelude Therapeutics's price shows low sensitivity to headline-driven sentiment. Peers average a sentiment sensitivity of -0.18. is expected not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is expected to be very small, whereas the daily expected return is at this time at 1.6%. %. The volatility of peer sentiment impact on Prelude Therapeutics is about 7263.16%, with the expected peer-implied price after the next announcement near 4.97. About 14.0% of PRLD outstanding shares are owned by corporate insiders. PRLD reported a loss per share of 1.29. Prelude Therapeutics had not issued any dividends in recent years. Given a 90-day horizon, the next expected press release will be within a week. Prelude Therapeutics Basic Forecasting Models add a structured statistical layer to the projection analysis for Prelude Therapeutics.The fundamentals of trading Prelude Stock are covered in our How to Buy Prelude Therapeutics walkthrough. This resource outlines the process for evaluating Prelude Stock from a trading perspective. It covers the mechanics of investing in Prelude Therapeutics from account funding through order execution.Related Market Sentiment Analysis
The comparative sentiment analysis table for Prelude Therapeutics provides risk metrics for Prelude Therapeutics' direct competitors. Value-at-risk and maximum drawdown for Prelude Therapeutics' competitors provide context for assessing Prelude Therapeutics's relative risk. Analyzing how Prelude Therapeutics' sector peers have historically reacted to news helps model sentiment dynamics around Prelude Therapeutics. The peer comparison framework for Prelude Therapeutics makes it possible to benchmark Prelude Therapeutics' news sensitivity against direct competitors.
| SentimentElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| PYXS | Pyxis Oncology | -0.32 | 5 per month | 3.81 | 0.13 | 11.11 | -7.37 | 24.00 | |
| OBIO | Orchestra BioMed Holdings | 0.00 | 0 per month | 2.62 | 0.06 | 5.58 | -4.88 | 13.46 | |
| ENTA | Enanta Pharmaceuticals | 0.00 | 0 per month | 3.23 | 0.09 | 4.16 | -4.51 | 20.18 | |
| CRBU | Caribou Biosciences | -0.18 | 2 per month | 3.71 | 0.11 | 8.64 | -5.75 | 20.34 | |
| IVA | Inventiva Sa | 0.00 | 0 per month | 0.00 | -0.02 | 5.89 | -4.75 | 15.53 | |
| TNYA | Tenaya Therapeutics | -0.32 | 13 per month | 4.99 | 0.04 | 8.96 | -7.46 | 49.49 | |
| AVTX | Avalo Therapeutics | 0.00 | 0 per month | 4.07 | 0.15 | 9.46 | -8.39 | 22.67 | |
| EPRX | Eupraxia Pharmaceuticals Common | 0.00 | 0 per month | 0.00 | -0.05 | 4.66 | -4.65 | 15.49 | |
| IMRX | Immuneering Corp | 0.00 | 0 per month | 3.21 | 0.09 | 6.28 | -4.98 | 18.27 | |
| FHTX | Foghorn Therapeutics | -0.32 | 12 per month | 0.00 | -0.03 | 5.51 | -5.70 | 21.52 |
Prelude Therapeutics Additional Predictive Modules
Estimating Prelude's future direction requires layering technical signals with statistical measures of trend persistence and volatility. Predictive models for Prelude work best when confirmed by real-time indicator readings.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Sentiment Indicators & Methodology
Sentiment analysis for Prelude Therapeutics evaluates news tone, positioning, and narrative momentum. Tone dispersion can increase uncertainty and volatility clustering. Prelude Therapeutics has a market cap of 371.93 million, ROE of -99.45%.
Prelude Therapeutics analytics rely on periodic company reporting and market reference feeds, with quality checks and normalization applied.
Editorial review and methodology oversight provided by: Gabriel Shpitalnik, Member of Macroaxis Editorial Board